PROMUS Element Everolimus-Eluting Coronary Stent System European Post- Approval Surveillance Study To Evaluate Real World Clinical Outcomes Data for the PROMUS Element Coronary Stent System in Unselected Patients in Routine Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms PE-Prove
- Sponsors Boston Scientific Corporation
- 01 Feb 2017 Status changed from active, no longer recruiting to completed.
- 18 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Feb 2011 Additional locations identified as reported by ClinicalTrials.gov.